ArticleInvestigative ophthalmology & visual science2026
Impaired P4HA1-Driven Hydroxyproline Formation Mediates Scleral Collagen Disruption in Form-Deprivation Myopia.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Scleral extracellular matrix (ECM) remodeling is a hallmark of myopia progression, yet its metabolic drivers remain poorly defined. This study investigated whether disruption of arginine-proline metabolism-specifically impaired P4HA1-mediated proline hydroxylation-contributes to hydroxyproline deficiency, collagen disorganization, and axial elongation in form-deprivation myopia (FDM). Methods: Monocular FDM was induced in guinea pigs for two weeks. Refractive errors, axial length, scleral morphology, and collagen ultrastructure were assessed. Untargeted and targeted metabolomics were performed to characterize metabolic alterations. AAV8-P4HA1 or control vector was delivered via sub-Tenon's capsule injection to the form-deprived eyes of two animal subgroups to test whether restoration of P4HA1 expression could rescue metabolic and structural abnormalities. Pharmacological inhibition of P4HA (1,4-DPCA) in cultured primary fibroblasts evaluated the cellular consequences of impaired proline hydroxylation. Results: Relative to untreated eyes, FDM resulted in a myopic refractive shift, axial elongation, and scleral thinning, reduced collagen fibril diameter, and ECM disorganization. Metabolomic analyses revealed disruption of arginine-proline metabolism, with elevated arginine and proline but reduced hydroxyproline, accompanied by increased ARG1, OAT, and PYCR1 expression and decreased P4HA1 and P4HA3 expression. P4HA1 overexpression restored hydroxyproline levels, corrected the metabolic imbalance, increased COL1A1, reduced MMP2, reinstated TIMP2, and improved collagen density and alignment, thereby mitigating axial elongation. Pharmacological inhibition of P4HA reduced hydroxyproline and collagen production. Conclusions: Reduced scleral P4HA1 expression in FDM eyes is associated with reduced scleral hydroxyproline content and collagen structural disorganization. That restoration of scleral P4HA1 levels inhibits FD-related excessive axial elongation points to the P4HA1-hydroxyproline axis as a potential target for myopia control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.